14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
IFLO vs ACAD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over VictoryShares International Free Cash Flow ETF (IFLO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IFLO carries a Unified Composite Score of 35.7/100 (SELL) at $33.75 (N/M Forward P/E, N/A operating margin), whereas ACAD carries 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin).
Technical & Structure Timing Caution: IFLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IFLO vs ACAD. Trailing 12-month operating profitability (IFLO N/A vs ACAD 10.2%) and valuation multiples (IFLO N/M vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment53.7% of Rev ($646M)
90D Engineering Disclosures0 Published
Investor FAQ IFLO vs ACAD Key Questions & Quantitative Answers
As of Nov 20, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over VictoryShares International Free Cash Flow ETF (IFLO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IFLO carries a Unified Composite Score of 35.7/100 (SELL) at $33.75 (N/M Forward P/E, N/A operating margin), whereas ACAD carries 44.8/100 (HOLD) at $17.11 (15.8x Forward P/E, 10.2% operating margin). Technical & Structure Timing Caution: IFLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACAD leads the Growth & Scale pillar: IFLO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). On trailing 12-month operating scale, IFLO generates N/A in USD-normalized revenue versus $1.20B for ACAD. In operating R&D and SG&A reinvestment, IFLO deploys N/A (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.
ACAD screens cheaper on headline valuation multiples. IFLO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ACAD trades at 15.8x Forward P/E, 8.3x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IFLO (N/A ROE) versus ACAD (31.4% ROE) capital efficiency.
In options market volatility and institutional positioning, IFLO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.76β · 18% Vol realized risk). By comparison, ACAD carries 41.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 71.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.